Paternal Valproate Treatment and Risk of Childhood Neurodevelopmental Disorders: Precautionary Regulatory Measures Are Insufficiently Substantiated.

Autor: Garey JD; Reproductive Toxicology Center, A Non-Profit Foundation, Washington, DC, USA., Damkier P; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.; Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark., Scialli AR; Reproductive Toxicology Center, A Non-Profit Foundation, Washington, DC, USA., Lusskin S; Division of Medical Genetics, Department of Pediatrics, Saint Louis University School of Medicine, St. Louis, Missouri, USA., Braddock SR; Regional Center of Pharmacovigilance, Department of Pharmacology, Cochin Port Royal Hospital, APHP, Paris, France., Chouchana L; The Rotunda Hospital, Dublin, Ireland., Cleary B; School of Pharmacy and Biomedical Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.; Department of Psychiatry and Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Conover EA; Division of Clinical Genetics, Munroe Meyer Institute, University of Nebraska Medical Center, Omaha, Nebraska, USA., Diav-Citrin O; The Israeli Teratology Information Service, Ministry of Health, Jerusalem, Israel.; The Hebrew University Hadassah Medical School, Jerusalem, Israel., Dragovich RS; Department of Internal Medicine, Northeast Ohio Medical University, Rootstown, Ohio, USA., Garcia-Bournissen F; Department of Paediatrics, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada., Hodson K; UK Teratology Information Service, Newcastle upon Tyne, UK., Kennedy D; Royal Hospital for Women, Randwick, New South Wales, Australia., Lamm SH; Center for Epidemiology and Maternal-Child Health (CEOH), Washington, DC, USA., Lavigne SA; MotherToBaby Connecticut, Division of Medical Genetics, UConn Health, Farmington, Connecticut, USA., Običan SG; Department of Obstetrics and Gynecology, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA., Panchaud A; Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.; Service of Pharmacy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland., Perrotta K; Department of Pediatrics, University of California, San Diego, La Jolla, California, USA., Romeo AN; MotherToBaby Utah, Utah Department of Health, Salt Lake City, Utah, USA., Shechtman S; The Israeli Teratology Information Service, Ministry of Health, Jerusalem, Israel., Weber-Schoendorfer C; Charité - Universitätsmedizin Berlin, Pharmakovigilanzzentrum Embryonaltoxikologie, Institut für Klinische Pharmakologie und Toxikologie, Berlin, Germany.
Jazyk: angličtina
Zdroj: Birth defects research [Birth Defects Res] 2024 Aug; Vol. 116 (8), pp. e2392.
DOI: 10.1002/bdr2.2392
Abstrakt: On January 12, 2024 the safety committee of the European Medicines Agency (EMA) recommended precautionary measures over a potential risk of neurodevelopmental disorders in children born to men treated with valproate. These new measures recommend patient supervision by a specialist in the management of epilepsy, bipolar disorder, or migraine. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) issued a far more stringent precaution, warning against prescribing valproate to anyone under 55 years of age. We, members of the European Network of Teratology Information Services (ENTIS) and the Organization of Teratology Information Specialists (OTIS), believe that the EMA and MHRA warnings were premature. We are of the opinion that the underlying scientific data do not convincingly substantiate the inference of a paternally mediated risk from valproate to children, much less to an extent that justifies these far-reaching recommendations.
(© 2024 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: